Close

HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

WHO Supplies Medical Equipment for Post-Marburg...

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK...

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences...

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized...

The Human Medicines Regulations 2025, which came into force...

Heart Test Laboratories, Inc. a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool through the use of Artificial Intelligence (AI)  announced that it has entered into a multi-year collaboration agreement with Rutgers University (Rutgers), one of America’s leading public research universities.

HeartSciences and Rutgers will collaborate to develop AI-based ECG algorithms, which are expected to accelerate HeartSciences’ product development pipeline and further expand the clinical value of an ECG for low-cost detection of heart disease. Partho P. Sengupta, MD, MBBS, FACC, Professor and the Chief of Division of Cardiology at Rutgers Robert Wood Johnson Medical School and the Robert Wood Johnson University Hospital, will serve as Rutgers’ Principal Investigator. These collaboration efforts will be focused on leveraging the extensive clinical data compiled at Rutgers. The collaboration agreement follows HeartSciences’ recent participation and demonstration of the MyoVista® at the Inauguration Ceremony of the Center for Innovation at the Rutgers and Robert Wood Johnson University Hospital in September 2022. The new collaborative relationship will operate out of the new Rutgers Robert Wood Johnson, Center for Innovation.

Dr. Sengupta stated, “We look forward to strengthening our existing relationship with HeartSciences for innovating in the important area of leveraging AI to expand the clinical capabilities of an ECG. AI is playing an important role in developing and advancing innovations in cardiology and has demonstrated significant potential for enhancing electrocardiography to improve heart disease detection, while reducing overall healthcare costs.”

Andrew Simpson, CEO of HeartSciences, stated, “We are excited and honored to enter a collaboration with Dr. Sengupta and Rutgers University. Dr. Sengupta is a globally respected figure in the field of cardiology, including the application of technology to accelerate innovation in the field of cardiology.  We have worked with Dr. Sengupta and his team in the past, with multiple published studies using MyoVista technology. This collaboration formalizes a multi-year arrangement with Rutgers, which we believe will significantly accelerate our product development pipeline of new ECG algorithms for front-line physicians and other healthcare providers.  There are millions of ECGs conducted every week and this collaboration reaffirms HeartSciences’ position at the leading edge of bringing new clinical capabilities to the ECG.”

Latest stories

Related stories

WHO Supplies Medical Equipment for Post-Marburg Virus Heal

In a recent move, the World Health Organization has...

Life Sciences Sector Plan Sets UK on Global Growth Track

Main Article: UK Life Sciences Sector Plan Sets Sights...

UK Government Launches Ambitious Life Sciences Sector Plan

Government Unveils Life Sciences Roadmap for Growth and Innovation London,...

Highly Customized Treatments to Offer Specialized Care to UK

The Human Medicines Regulations 2025, which came into force...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back